Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Maze Therapeutics, Inc.NASDAQ: MAZE
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 32.5% from a year ago
Cash & equivalents stood at $198.77M at the end of Q1 FY2026, down 32.5% from a year earlier and up 5.0% from the prior quarter. Over 3 fiscal years it compounded at +23.7% a year.
Context
- Cash & equivalents amounted to 47.4% of total assets at the end of Q1 FY2026, down 41.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -32.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 189.25M USD
- Year-over-year change
- -3.8%
- 3-year CAGR
- +23.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 189.25M | -3.8% |
| FY2024 | 2024-12-31 | 196.81M | +575.0% |
| FY2023 | 2023-12-31 | 29.16M | -70.8% |
| FY2022 | 2022-12-31 | 99.92M | — |
Cash & Equivalents vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -32.5% is the 7th highest of 8, against a peer median of +2.8%.
- Cash & equivalents amounts to 47.4% of total assets for MAZE, versus a peer median of 27.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.05B USD | +3.2% | +52.1% | 32.3% | |
BIOABioAge Labs, Inc. | Mar 2026 | $241.78M USD | -6.1% | +89.8% | 60.8% |
| Mar 2026 | $198.77M USD | -32.5% | +23.7% | 47.4% | |
SEPNSepterna, Inc. | Sep 2026 | $167.12M USD | -47.8% | +58.0% | 27.0% |
| Sep 2026 | $123.54M USD | +11.4% | +14.7% | 14.6% | |
| Dec 2025 | €99.27M EUR | +2.8% | +4.6% | 39.9% | |
| Mar 2026 | $31.21M USD | +1.3% | -10.9% | 6.2% | |
| Mar 2026 | $4.87M USD | +88.0% | +49.0% | 9.2% | |
| Peer median (excluding MAZE) | — | +2.8% | +49.0% | 27.0% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.